E-viri
PDF
Recenzirano
Odprti dostop
-
Taylor, Alexander M; Vaswani, Rishi G; Gehling, Victor S; Hewitt, Michael C; Leblanc, Yves; Audia, James E; Bellon, Steve; Cummings, Richard T; Côté, Alexandre; Harmange, Jean-Christophe; Jayaram, Hari; Joshi, Shivangi; Lora, Jose M; Mertz, Jennifer A; Neiss, Adrianne; Pardo, Eneida; Nasveschuk, Christopher G; Poy, Florence; Sandy, Peter; Setser, Jeremy W; Sims, Robert J; Tang, Yong; Albrecht, Brian K
ACS medicinal chemistry letters, 02/2016, Letnik: 7, Številka: 2Journal Article
Inhibition of the bromodomains of the BET family, of which BRD4 is a member, has been shown to decrease myc and interleukin (IL) 6 in vivo, markers that are of therapeutic relevance to cancer and inflammatory disease, respectively. Herein we report substituted benzobisoxazolo4,5-dazepines and benzotriazolo4,3-d1,4diazepines as fragment-derived novel inhibitors of the bromodomain of BRD4. Compounds from these series were potent and selective in cells, and subsequent optimization of microsomal stability yielded representatives that demonstrated dose- and time-dependent reduction of plasma IL-6 in mice.
